{"id":20588,"date":"2026-06-15T15:42:29","date_gmt":"2026-06-15T15:42:29","guid":{"rendered":"https:\/\/www.rawoodfoundation.org\/?p=20588"},"modified":"2026-06-15T15:42:30","modified_gmt":"2026-06-15T15:42:30","slug":"momentum-is-building-reflections-from-the-first-mc4r-pathway-summit","status":"publish","type":"post","link":"https:\/\/www.rawoodfoundation.org\/fr\/2026\/06\/15\/momentum-is-building-reflections-from-the-first-mc4r-pathway-summit\/","title":{"rendered":"Momentum is Building: Reflections from the First MC4R Pathway Summit"},"content":{"rendered":"

Coming together to advance understanding of MC4R pathway diseases and acquired hypothalamic obesity.<\/h2>\n\n\n\n
\"Bonnie,<\/figure>\n\n\n\n

Bonnie (Ian’s mom), Ian (cranio survivor with aHO) and Kat (mom of Reid, living with BBS) share their stories at Momentum: the MC4r Pathway Summit.<\/em><\/p>\n\n\n\n

\n\n\n\n

On June 12, 2026, clinicians, researchers, industry leaders, patients, and caregivers gathered in Chicago for the first-ever MOMENTUM: the MC4R Pathway Summit, hosted by Rhythm Pharmaceuticals ahead of the Endocrine Society’s annual meeting (ENDO 2026).<\/p>\n\n\n\n

Despite weather-related travel disruptions, participants joined both in person and virtually for a day dedicated to advancing understanding of MC4R pathway diseases and acquired hypothalamic obesity (aHO)\u2014conditions that profoundly impact many survivors of hypothalamic-pituitary brain tumors.<\/p>\n\n\n\n

For those of us in the hypothalamic syndrome community, the summit felt like something more than a scientific meeting. It truly felt like momentum.<\/p>\n\n\n\n

The summit was chaired by Dr. Odelia Cooper of Cedars-Sinai Medical Center and Dr. Brooke Sweeney of Children’s Mercy Kansas City, who brought together experts from across disciplines to explore the complex challenges associated with MC4R pathway impairment and hypothalamic dysfunction.<\/p>\n\n\n\n

Topics ranged from recognizing and diagnosing acquired hypothalamic obesity in clinical practice to the neurocognitive manifestations of MC4R pathway diseases. Speakers also addressed the realities of hyperphagia, food noise, obesity management, and the lived experiences of patients and families navigating rare forms of obesity.<\/p>\n\n\n\n

Several themes emerged throughout the day.<\/p>\n\n\n\n

The Challenges of Diagnosis<\/h3>\n\n\n\n

One recurring discussion centered on how little is still understood about diagnosing acquired hypothalamic obesity, particularly in adults. For many survivors of craniopharyngioma and other hypothalamic-pituitary tumors, obesity may already be present before treatment, making it difficult to distinguish between common obesity and obesity driven by hypothalamic injury.<\/p>\n\n\n\n

As awareness grows, clinicians are increasingly recognizing the need for better diagnostic criteria, improved screening tools, and greater education across healthcare settings.<\/p>\n\n\n\n

Hypothalamic Syndrome Is More Than Weight Gain<\/h3>\n\n\n\n

The summit reinforced an important reality that patients and caregivers have long known: hypothalamic syndrome is not simply a weight-management issue.<\/p>\n\n\n\n

Presentations highlighted the wide range of symptoms that can affect quality of life, including:<\/p>\n\n\n\n